Stifel cuts Regenxbio stock price target to $42 on gene therapy data
#Stifel #Regenxbio #stock price target #gene therapy #biotechnology #investment #financial analysis #pharmaceuticals
📌 Key Takeaways
- Stifel lowered Regenxbio's stock price target to $42.
- The adjustment is based on recent gene therapy data.
- The move reflects a reassessment of the company's value.
- Gene therapy performance directly influenced the financial outlook.
🏷️ Themes
Biotech Finance, Gene Therapy
📚 Related People & Topics
Stifel
American investment bank
Stifel Financial Corp. is an American multinational independent investment bank and financial services company created under the Stifel name in July 1983 and listed on the New York Stock Exchange on November 24, 1986. Its predecessor company was founded in 1890 as the Altheimer and Rawlings Investme...
Entity Intersection Graph
Connections for Stifel:
🏢
Ciena
1 shared
🏢
Alcon
1 shared
🏢
Anadarko Petroleum
1 shared
🌐
Middle East
1 shared
🌐
EPR Properties
1 shared
Mentioned Entities
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Trump replaces Homeland Security chief Kristi Noem Oil extends weekly gains as Iran conflict rages on, with crude surging around 20% Gold prices dip as stronger dollar weighs; Iran conflict remains in focus Dollar resumes climb on safe haven demand as Iran conflict rages on (South Africa Philippines Nigeria) Stifel cuts Regenxbio stock price target to $42 on gene therapy data By Analyst Ratings Published 03/05/2026, 03:01 PM Stifel cuts Regenxbio stock price target to $42 on gene therapy data 0 RGNX -5.79% Investing.com - Stifel lowered its price target on Regenxbio Inc. (NASDAQ:RGNX) to $42 from $45 while maintaining a Buy rating on the gene therapy company’s shares. The stock currently trades at $8.49, well below the analyst consensus target, with Wall Street analysts maintaining a Strong Buy rating and price targets ranging from $12 to $50. The firm said Regenxbio is moving toward pivotal data readouts for RGX-202 in Duchenne muscular dystrophy in early second quarter 2026 and ABBV-RGX-314 in wet age-related macular degeneration in fourth quarter 2026. Stifel said the company has among the most comprehensive datasets in gene therapy. Regenxbio and AbbVie are dosing the first patient for Phase 2/3 diabetic retinopathy studies at dose level 3, identified as the ideal dose for efficacy and safety. The company expects additional information at the Muscular Dystrophy Association meeting next week for insight into safety and durability of functional benefit ahead of the RGX-202 readout. The company has faced regulatory setbacks on RGX-121 for MPS-II but believes it has the data needed to lift the clinical hold and compile a resubmission addressing points of the complete response letter. Regenxbio believes RGX-202 will be considered separate from RGX-121 by the Food and Drug Administration. Regenxbio had $240.9 million in cash giving it runway into 2027, with an additional $100 million coming from AbbVie, accordi...
Read full article at source